Bengaluru: OneSource Specialty Pharma Limited (BSE: 544292, NSE: ONESOURCE) announced its Q2FY26 financial results, reporting a 12% year-on-year (YoY) increase in revenue to ₹3,758 million and a strong EBITDA growth of 37% YoY to ₹1,065 million (OneSource Q2FY26).
The EBITDA margin expanded by 506 basis points (bps), reaching 28%. The company posted an adjusted profit after tax (PAT) of ₹449 million, translating to an adjusted EPS of ₹3.9.
Also Read: Emcure Pharmaceuticals Q2FY26 Results: INR 2,270 Cr Revenue and 25 Per Cent Profit Growth
OneSource Q2FY26 Financial Performance Highlights
- Revenue: ₹3,758 million, up 12% YoY
- EBITDA: ₹1,065 million, up 37% YoY
- EBITDA Margin: 28%, up ~506 bps YoY
- Adjusted PAT: ₹449 million
- Adjusted EPS: ₹3.9
For the first half of FY26, OneSource reported consolidated revenues of ₹7,030 million, reflecting a 12% YoY growth, and EBITDA of ₹1,950 million, up 37% YoY.
OneSource Q2FY26: Growth Driven by IP-led Business and MSA Executions
Neeraj Sharma, CEO and Managing Director of OneSource Specialty Pharma Limited, said, “Our second-quarter performance was driven by MSA executions and sales from our IP-led base business. We are accelerating DDC capacity expansion to support upcoming customer launches.”
He added, “The recently approved proposed acquisitions – a multi-dose fill-finish site in Europe and an integrated carbapenem facility in India – position us well for long-term growth. Accordingly, we are raising our FY28 revenue outlook to exceed $500 million.”
Also Read: The Lancet Recognizes Type 5 Diabetes Linked to Chronic Undernutrition in Developing Nations
Strategic Acquisitions Strengthen OneSource Q2FY26 Outlook
The recently announced proposed acquisition of Poland and Brooks entities delivered strong first-half results, with combined revenues of $29 million and EBITDA of $11 million, translating into healthy margins of 38%.
With its five globally approved manufacturing facilities, over 1,400 professionals, and strong regulatory compliance, OneSource continues to strengthen its position as a leading specialty pharmaceutical contract development and manufacturing organization (CDMO).
